Journey Medical Corporation Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
Globe Newswire•12/11/2026•16:01 ET
2
Key Highlights
- ➤Emrosi revenue $9.0 million, up 84% year over year
- ➤Third-quarter revenue $19.0 million, up 8% year over year
- ➤GAAP net loss narrowed to $1.3 million, or $0.05 per share
- ➤Adjusted EBITDA reached $3.5 million, versus $1.4 million last year
- ➤Cash and equivalents totaled $22.3 million at September 30, 2026
Expert Statements
Claude Maraoui, Co-Founder, President and Chief Executive Officer of Journey Medical
“We continued to make progress during the third quarter, delivering year-over-year revenue growth, a higher gross margin, and positive EBITDA”
Claude Maraoui, Co-Founder, President and Chief Executive Officer of Journey Medical
“Third quarter sales of Emrosi®, our best-in-class oral rosacea treatment, increased by 84% compared to the prior-year period, driven by growth in prescription demand and continued improvement in the mix of prescriptions reimbursed by health plans.”
Claude Maraoui, Co-Founder, President and Chief Executive Officer of Journey Medical
“The number of unique prescribers writing for Emrosi® increased again during the third quarter and strong refill trends on top of new prescription growth are fueling momentum behind the brand and indicate high patient satisfaction with the product.”
Claude Maraoui, Co-Founder, President and Chief Executive Officer of Journey Medical
“Our recently expanded sales force and increasing formulary additions with national health plans are expected to facilitate further adoption and market penetration.”
Claude Maraoui, Co-Founder, President and Chief Executive Officer of Journey Medical
“Building on this progress and with over $22 million in cash, we believe we are well-positioned to advance our mission of delivering value to our dermatology customers and their patients while building long-term shareholder value.”
Total revenues were $19.0 million for the third quarter of 2026
Emrosi(®) revenues of $9.0 million increased 84% compared to the third quarter of 2025
Get started
Create a free account to read the full story.